tetano
Editor, Senior Moderator
Clin Pharmacol Ther
. 2020 May 21.
doi: 10.1002/cpt.1909. Online ahead of print.
Prioritisation of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived From Their Established Human Pharmacokinetics
Usman Arshad[SUP] 1 [/SUP], Henry Pertinez[SUP] 1 [/SUP], Helen Box[SUP] 1 [/SUP], Lee Tatham[SUP] 1 [/SUP], Rajith Kr Rajoli[SUP] 1 [/SUP], Paul Curley[SUP] 1 [/SUP], Megan Neary[SUP] 1 [/SUP], Joanne Sharp[SUP] 1 [/SUP], Neill J Liptrott[SUP] 1 [/SUP], Anthony Valentijn[SUP] 1 [/SUP], Christopher David[SUP] 1 [/SUP], Steve P Rannard[SUP] 2 [/SUP], Paul M O'Neill[SUP] 2 [/SUP], Ghaith Aljayyoussi[SUP] 3 [/SUP], Shaun Pennington[SUP] 3 [/SUP], Stephen A Ward[SUP] 3 [/SUP], Andrew Hill[SUP] 1 [/SUP], David J Back[SUP] 1 [/SUP], Saye H Khoo[SUP] 1 [/SUP], Patrick G Bray[SUP] 4 [/SUP], Giancarlo A Biagini[SUP] 3 [/SUP], Andrew Owen[SUP] 1 [/SUP]
Affiliations
Abstract
There is a rapidly expanding literature on the in vitro antiviral activity of drugs that may be repurposed for therapy or chemoprophylaxis against SARS-CoV-2. However, this has not been accompanied by a comprehensive evaluation of the target plasma and lung concentrations of these drugs following approved dosing in humans. Accordingly, EC[SUB]90[/SUB] values recalculated from in vitro anti-SARS-CoV-2 activity data was expressed as a ratio to the achievable maximum plasma concentrations (Cmax) at an approved dose in humans (Cmax/EC[SUB]90[/SUB] ratio). Only 14 of the 56 analysed drugs achieved a Cmax/EC[SUB]90[/SUB] ratio above 1. A more in-depth assessment demonstrated that only nitazoxanide, nelfinavir, tipranavir (ritonavir-boosted) and sulfadoxine achieved plasma concentrations above their reported anti-SARS-CoV-2 activity across their entire approved dosing interval. An unbound lung to plasma tissue partition coefficient (K[SUB]p[/SUB] U[SUB]lung[/SUB] ) was also simulated to derive a lung Cmax/EC[SUB]50[/SUB] as a better indicator of potential human efficacy. Hydroxychloroquine, chloroquine, mefloquine, atazanavir (ritonavir-boosted), tipranavir (ritonavir-boosted), ivermectin, azithromycin and lopinavir (ritonavir-boosted) were all predicted to achieve lung concentrations over 10-fold higher than their reported EC[SUB]50[/SUB] . Nitazoxanide and sulfadoxine also exceeded their reported EC[SUB]50[/SUB] by 7.8- and 1.5-fold in lung, respectively. This analysis may be used to select potential candidates for further clinical testing, while deprioritising compounds unlikely to attain target concentrations for antiviral activity. Future studies should focus on EC[SUB]90[/SUB] values and discuss findings in the context of achievable exposures in humans, especially within target compartments such as the lung, in order to maximise the potential for success of proposed human clinical trials.
Keywords: COVID-19; Coronavirus; Lung; Pharmacokinetics; SARS-CoV-2.
. 2020 May 21.
doi: 10.1002/cpt.1909. Online ahead of print.
Prioritisation of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived From Their Established Human Pharmacokinetics
Usman Arshad[SUP] 1 [/SUP], Henry Pertinez[SUP] 1 [/SUP], Helen Box[SUP] 1 [/SUP], Lee Tatham[SUP] 1 [/SUP], Rajith Kr Rajoli[SUP] 1 [/SUP], Paul Curley[SUP] 1 [/SUP], Megan Neary[SUP] 1 [/SUP], Joanne Sharp[SUP] 1 [/SUP], Neill J Liptrott[SUP] 1 [/SUP], Anthony Valentijn[SUP] 1 [/SUP], Christopher David[SUP] 1 [/SUP], Steve P Rannard[SUP] 2 [/SUP], Paul M O'Neill[SUP] 2 [/SUP], Ghaith Aljayyoussi[SUP] 3 [/SUP], Shaun Pennington[SUP] 3 [/SUP], Stephen A Ward[SUP] 3 [/SUP], Andrew Hill[SUP] 1 [/SUP], David J Back[SUP] 1 [/SUP], Saye H Khoo[SUP] 1 [/SUP], Patrick G Bray[SUP] 4 [/SUP], Giancarlo A Biagini[SUP] 3 [/SUP], Andrew Owen[SUP] 1 [/SUP]
Affiliations
- PMID: 32438446
- DOI: 10.1002/cpt.1909
Abstract
There is a rapidly expanding literature on the in vitro antiviral activity of drugs that may be repurposed for therapy or chemoprophylaxis against SARS-CoV-2. However, this has not been accompanied by a comprehensive evaluation of the target plasma and lung concentrations of these drugs following approved dosing in humans. Accordingly, EC[SUB]90[/SUB] values recalculated from in vitro anti-SARS-CoV-2 activity data was expressed as a ratio to the achievable maximum plasma concentrations (Cmax) at an approved dose in humans (Cmax/EC[SUB]90[/SUB] ratio). Only 14 of the 56 analysed drugs achieved a Cmax/EC[SUB]90[/SUB] ratio above 1. A more in-depth assessment demonstrated that only nitazoxanide, nelfinavir, tipranavir (ritonavir-boosted) and sulfadoxine achieved plasma concentrations above their reported anti-SARS-CoV-2 activity across their entire approved dosing interval. An unbound lung to plasma tissue partition coefficient (K[SUB]p[/SUB] U[SUB]lung[/SUB] ) was also simulated to derive a lung Cmax/EC[SUB]50[/SUB] as a better indicator of potential human efficacy. Hydroxychloroquine, chloroquine, mefloquine, atazanavir (ritonavir-boosted), tipranavir (ritonavir-boosted), ivermectin, azithromycin and lopinavir (ritonavir-boosted) were all predicted to achieve lung concentrations over 10-fold higher than their reported EC[SUB]50[/SUB] . Nitazoxanide and sulfadoxine also exceeded their reported EC[SUB]50[/SUB] by 7.8- and 1.5-fold in lung, respectively. This analysis may be used to select potential candidates for further clinical testing, while deprioritising compounds unlikely to attain target concentrations for antiviral activity. Future studies should focus on EC[SUB]90[/SUB] values and discuss findings in the context of achievable exposures in humans, especially within target compartments such as the lung, in order to maximise the potential for success of proposed human clinical trials.
Keywords: COVID-19; Coronavirus; Lung; Pharmacokinetics; SARS-CoV-2.